Abstract: An implantable medical electrical lead particularly for stimulation of the sacral nerves comprises a lead body extending between a distal end and a proximal end, and the distal end having at least one electrode of an electrode array extending longitudinally from the distal end toward the proximal end. The lead body at its proximal end may be coupled to a pulse generator, additional intermediate wiring, or other stimulation device. A fixation mechanism is formed on or integrally with the lead body proximal to the electrode array that is adapted to be implanted in and engage subcutaneous tissue, particularly muscle tissue, to inhibit axial movement of the lead body and dislodgement of the stimulation electrodes. The fixation mechanism comprises a M tine elements arrayed in a tine element array along a segment of the lead proximal to the stimulation electrode array.
Type:
Grant
Filed:
April 28, 2004
Date of Patent:
February 12, 2008
Assignee:
Medtronic, Inc.
Inventors:
John M. Swoyer, Keith Carlton, Martin T. Gerber, George J. Mamo, Michele Spinelli, Steven David Hartle
Abstract: A gastroelectric stimulator comprises a neurostimulator for producing a stimulation signal, at least one electrical lead, and at least two electrical contacts. The electrical lead has a proximal end and a distal end, the proximal end being connected to the neurostimulator and the distal end positionable in a lead position within the patient's abdomen. The electrodes are carried near the electrical lead distal end. The electrodes are electrically connected through the electrical lead to the neurostimulator to receive the stimulation signal and convey this signal to an electrode position within the patient's digestive system. The stimulation signal is adapted to influence pancreatic secretions.
Abstract: Delivery elements, including needle electrodes and sheaths of tissue ablation devices, containing a conductivity-enhancing agent are discussed. The delivery elements contain a body member and optionally one or more coating layers. The conductivity-enhancing agent is disposed on or in the body member and/or at least one of the one or more coating layers. The conductivity-enhancing agent is capable of eluting from the delivery element when the delivery element is contacted with bodily tissue or fluid and increases conductivity of the tissue, making tissue ablation more efficient.
Type:
Grant
Filed:
April 30, 2004
Date of Patent:
June 27, 2006
Assignee:
Medtronic, Inc.
Inventors:
John M. Swoyer, Yelena G. Tropsha, Julie M. Woessner, Mark A. Christopherson
Abstract: The invention provides an implantable trial neurostimulator. The implantable trial neurostimulator may be equipped with limited, short-term battery resources. The limited battery resources are designed to last for a finite period of time, thereby preventing a patient or physician from prolonging the trial neurostimulation period. For example, the implantable trial neurostimulator may be designed to stop functioning after a number of days or weeks, upon exhaustion of the battery resources. Alternatively, the implantable trial neurostimulator may be disabled upon expiration of a timer. The trial neurostimulator may be temporarily implanted in a subdural pocket in which the chronic stimulator is ultimately implanted. In this manner, the trial neurostimulator can be coupled to a chronic lead and avoid any percutaneous connections, reducing the risk of infection and affording greater convenience and comfort to patients.